|
Synonyms: BMS-986256 | BMS986256 | example 15 [US10478424]
Compound class:
Synthetic organic
Comment: Afimetoran (BMS-986256) is an orally bioavailable, small molecule, dual Toll-like receptor 7 and 8 (TLR7/8) antagonist [1]. It was designed as an immunomodulator for the treatment of inflammation and autoimmune diseases [3]. Afimetoran may also bind to the TLR adaptor protein toll-interacting protein (TOLLIP) [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Afimetoran (BMS-986256) was advanced as a clinical candidate for both the systemic and cutaneous forms of lupus erythematosus. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04895696 | A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | Phase 2 Interventional | Beeline Medicines Corporation | ||
| NCT07881120 | Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus | Phase 2/Phase 3 Interventional | Beeline Medicines Corporation | ||
| NCT04493541 | A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus | Phase 1 Interventional | Bristol-Myers Squibb | 3 | |